Newsroom – Page 2

ERYTECH and PHERECYDES announced their proposed strategic combination intended to create a global player in extended phage therapy and accelerate the development of a portfolio of drug candidates targeting pathogenic…

ERYTECH Provides Business and Financial Update for the Third Quarter of 2022

Post author:Cleo Sciscioli
Post published:November 21, 2022
Post category:Newsroom

Conference call and webcast on Tuesday, November 22, 2022 at 8:30am EST / 02:30pm CEST

ERYTECH Announces Receipt of Nasdaq Notice

Post author:Cleo Sciscioli
Post published:October 13, 2022
Post category:Newsroom

Erytech announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC regarding its American Depositary Shares ("ADSs")

ERYTECH Provides Business and Financial Update for the First Half of 2022

Post author:Marianne Duparc
Post published:September 12, 2022
Post category:Newsroom

ERYTECH Pharma today provided a business and financial update for the first half of 2022.

ERYTECH Provides Regulatory Update

Post author:Marianne Duparc
Post published:August 24, 2022
Post category:Newsroom

ERYTECH Pharma provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia (ALL) following feedback from the U.S. Food and Drug…